



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/17/2016
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

NEXAVAR® (sorafenib) oral tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "**Description**" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "**Criteria**" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/17/2016
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

NEXAVAR® (sorafenib) oral tablet

Criteria:

- **Criteria for initial therapy:** Nexavar (sorafenib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Oncologist, Gastroenterologist, or Nephrologist depending upon indication or use
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - a. Unresectable hepatocellular carcinoma (HCC)
 - b. Advanced renal cell carcinoma (RCC)
 - c. Locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment
 - d. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. **ALL** of the following baseline tests have been completed before initiation of treatment:
 - a. Negative pregnancy test in a woman of childbearing potential
 - b. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
 5. There are **NO** FDA-label contraindications, such as:
 - a. Nexavar in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer
 6. Individual is not on dialysis
 7. Individual does not have severe hepatic impairment (Child-Pugh Class C)
 8. There are no significant interacting drugs

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Nexavar (sorafenib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist, Gastroenterologist, or Nephrologist depending upon indication or use
 2. Individual's condition has responded while on therapy
 - a. Response is defined as:



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/17/2016
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

NEXAVAR® (sorafenib) oral tablet

- i. Documented evidence of efficacy, disease stability and/or improvement
 - ii. No evidence individual has developed any significant unacceptable adverse drug reactions that may exclude continued use
3. Individual has been adherent with the medication
 4. Individual has not developed any contraindications or other significant adverse drug effects that may exclude continued use
 - a. Contraindications as listed in the criteria for initial therapy section
 - b. Significant adverse effect such as:
 - i. Moderate or greater cardiac ischemia and/or infarction
 - ii. Life-threatening congestive heart failure
 - iii. Moderate or greater bleeding requiring medical intervention
 - iv. Severe or persistent or life-threatening hypertension despite use of anti-hypertensive therapy
 - v. Gastrointestinal perforation
 - vi. Severe or greater hepatotoxicity or unexplained transaminase elevations
 - vii. Any life-threatening non-hematologic toxicity
 - viii. 3rd occurrence of severe moist desquamation, ulceration, blistering, or severe pain of the hands or feet, resulting in inability to work or perform activities of daily living
 - ix. 4th occurrence of moderate painful erythema and swelling of the hands or feet and/or discomfort affecting the patient's normal activities
 - x. Severe or persistent cutaneous reactions, or if Stevens-Johnson syndrome and toxic epidermal necrolysis is suspected
 5. Individual is not on dialysis
 6. Individual does not have severe hepatic impairment (Child-Pugh Class C)
 7. There are no significant interacting drugs

Renewal duration: 12 months

➤ Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-cancer Medications**
2. **Off-Label Use of Cancer Medications**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 3/17/2016
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

NEXAVAR® (sorafenib) oral tablet

Description:

Nexavar (sorafenib) is indicated for the treatment of unresectable hepatocellular carcinoma; advanced renal cell carcinoma; and Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.

Nexavar (sorafenib) is a kinase inhibitor that decreases tumor cell proliferation. It inhibits multiple intracellular and cell surface kinases that are thought to be involved in tumor cell signaling, angiogenesis and apoptosis.

Resources:

Nexavar (sorafenib) product information, revised by Bayer HealthCare Pharmaceuticals, Inc. 07-2020. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 09, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hepatobiliary Cancers Version 5.2021 – Updated September 21, 2021. Available at <https://www.nccn.org>. Accessed December 09, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney Cancer Version 3.2022 – Updated November 04, 2021. Available at <https://www.nccn.org>. Accessed December 09, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Thyroid Carcinoma Version 3.2021 – Updated October 15, 2021. Available at <https://www.nccn.org>. Accessed December 09, 2021.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.